SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK ) today announced one oral presentation and two poster presentations at the 27th International Symposium on ALS/MND in Dublin, Ireland. The posters will be presented on Wednesday, December 7, 2016, and will include the results of an international physician survey on the use of noninvasive ventilation in the treatment of ALS, and data on a machine learning model for the prediction of slow vital capacity, based on datasets from BENEFIT-ALS that Origent Data Sciences analyzed under a research collaboration with Cytokinetics that is funded by The ALS Association. On Friday, December 9, 2016, the baseline characteristics of patients enrolled in VITALITY-ALS will be presented in an oral presentation.
Poster Presentations
Date : Wednesday, December 7, 2016 Location : The Forum, The Convention Centre Dublin Session : Poster Session A Presentation Time : 5:45 – 7:30 PM Poster Moderated : 6:00 – 6:20 PM Poster Number : P203 Theme : 7 - Improving Diagnosis and Prognosis Title : Machine Learning Model For The Prediction Of Slow Vital Capacity Poster Presenters : David L. Ennist, Ph.D., MBA, Chief Science Officer, Origent Data Sciences and Jinsy A. Andrews, M.D., Director of Neuromuscular Clinical Trials at Columbia University in New York City
Date : Wednesday, December 7, 2016 Location : The Forum, The Convention Centre Dublin Session : Poster Session A Presentation Time : 5:45 – 7:30 PM Poster Moderated : 7:00 – 7:20 PM Poster Number : CW3 Theme: CW - Clinical Work in Progress Title : Understanding the use of noninvasive ventilation in the treatment of amyotrophic lateral sclerosis: results of an international physician survey Poster Presenter : Terry Heiman-Patterson, M.D., Drexel Neurological Institute, Philadelphia
Oral Presentation
Date : Friday, December 9, 2016 Location : The Liffey B, The Convention Centre Dublin Session : 9B – Clinical Trials Presentation Time : 9:30 – 9:45 AM Title : VITALITY-ALS, a Phase 3 trial of the fast skeletal muscle troponin activator, Tirasemtiv , for the potential treatment of ALS: Study design and baseline characteristics Presenter : Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of VITALITY-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the University of Arizona, Phoenix
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv , a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv , subject to an option held by Astellas Pharma Inc. Cytokinetics is also collaborating with Astellas to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil , a novel cardiac muscle activator, for the potential treatment of heart failure. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/ .
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including the conduct, design, enrollment, progress and timing of results of the VITALITY-ALS Phase 3 clinical trial of tirasemtiv in patients with ALS; the significance and utility of preclinical study and clinical trial results; and the properties and potential efficacy and safety profile of tirasemtiv and Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, further clinical development of tirasemti v in ALS patients will require significant additional funding, and Cytokinetics may be unable to obtain such additional funding on acceptable terms, if at all; the FDA and/or other regulatory authorities may not accept effects on slow vital capacity as a clinical endpoint to support registration of tirasemtiv for the treatment of ALS; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics' collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Contact: Cytokinetics Diane Weiser Vice President, Corporate Communications, Investor Relations (415) 290-7757
